Determining the effects of treatments on vascular disease risk by meta-analyses using individual participant data

Lead Research Organisation: Medical Research Council

Abstract

This programme of research provides reliable evidence of the effects of treatment with common drugs, such as aspirin, other painkillers (NSAIDs), and statins. Since the effects of commonly used treatments are often modest, but important in terms of their long-term health consequences, studies generally require data on very large numbers of patients. Individual clinical trials on their own on such drugs are too small to assess such effects reliably, so we use a method called meta-analysis to examine aggregated data from all relevant trials. This involves collaborating with other scientists worldwide who have undertaken such trials, securing their agreement to provide the individual patient data, and then analysing this large amount of individual patient level data from the various trials to develop a more detailed understanding of the effects of particular treatments. For example, our previous work has helped to provide guidance on which people benefit from aspirin and statins, and has also provided useful information about the risks of NSAIDs. The results of these collaborative studies are widely used to guide doctors in the use of drug treatments internationally, and also help to identify which areas of research are required to tackle outstanding clinical questions.

Technical Summary

This programme of research determines the effects of common treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and statins, on the risk of vascular disease, whether as an intended benefit or as an unanticipated hazard, by conducting meta-analyses. We coordinate collaborations of trialists to conduct meta-analyses, using individual participant data contributed by investigators and sponsors, but analysed independently of the funding source of the trials. In each of the various collaborations, the effects and safety of the treatment under study can be assessed more reliably through the use of data from individual participants. In particular, it is possible to examine the effects of treatments on particular outcomes (with broadly similar definitions across different studies), assess possible variation in the effects of treatments in different types of patients, and assess the temporal evolution of treatment effects in relation to drug use. Our previous work has helped to resolve significant uncertainties about the treatment of common conditions in different patient groups. For example, the Antithrombotic Treatment Trialists’ (ATT) Collaboration has shown that, among patients who already have occlusive vascular disease, long-term antiplatelet therapy (e.g. with aspirin) reduces the annual risk of serious vascular event by about a quarter. This typically corresponds to an absolute reduction of about 10-20 per 1000 in the annual incidence of serious vascular events. Against this benefit, the absolute increase in major gastrointestinal or other major extracranial bleeds is about ten times smaller. Hence, for secondary prevention, it is widely agreed that the benefit of aspirin substantially exceeds risk. For primary prevention, however, the balance is less clear because the absolute vascular benefits of aspirin are an order of magnitude lower in this setting than in secondary prevention, and our work has shown that aspirin is not appropriate for primary prevention. Similarly, the Coxib and traditional NSAIDs Trialists’ (CNT) Collaboration has helped quantify the cardiovascular and gastrointestinal risks of non-steroidal anti-inflammatory drugs, which led to changes in drug-labelling for diclofenac in Europe, and the Cholesterol Treatment Trialists’ [CTT] Collaboration has documented the benefits and safety of statin therapy in a wide variety of people, including people at low risk of vascular disease, again influencing guidelines worldwide. Future work will address areas of uncertainty within existing meta-analyses (including, within the CTT for example, analyses of adverse events within trials of statin therapy), as well as tackling new questions, such as the balance of benefit and risk of rt-PA in ischaemic stroke within the Stroke Thrombolysis Trialists’ (STT) Collaboration.

Organisations

Publications

10 25 50
 
Guideline Title American Diabetes Association indications for statins in diabetes (Diabetes Care 2009; 32: S384-91)
Description American Diabetes Association indications for statins in diabetes
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
Impact Recommendation from ADA that all patients with diabetes receive a statin and that the target LDL cholesterol among them should be <2.6 mmol/L
 
Guideline Title European Guidelines on Cardiovascular Disease Prevention in Clinical Practice
Description European Guidelines on Cardiovascular Disease Prevention in Clinical Practice
Geographic Reach Asia 
Policy Influence Type Citation in clinical guidelines
Impact ESC clinical guidelines influence the management of cardiovascular disease in both primary and secondary care.
 
Description European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors
Geographic Reach Asia 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
Impact Our 2013 Lancet publication (see below) was cited in the press release as providing the new evidence that resulted in the EMA issuing updated guidance. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 30 May 2013 doi:10.1016/S0140-6736(13)60900-9
URL http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001816.js...
 
Guideline Title Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Description Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018.
Description Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials
Geographic Reach North America 
Policy Influence Type Citation in clinical guidelines
 
Guideline Title Acute Inpatient Stroke Care, 6th Edition, Update 2018
Description Impact of STT paper Effects of alteplase for acute stroke according to criteria defining the EU and US marketing authorizations: Individual-patient-data meta-analysis of randomized trials
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Influenced clinical guidelines
 
Description MRC Network of Hubs for Trials Methodology Research: Development of novel analysis methods in a systematic meta-analysis allowing indirect comparisons
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact The Vascular Overviews Group which runs various collaborative meta-analyses including the Cholesterol Treatment Trialists' Collaboration, Anti-thrombotic Treatment Trialists' Collaboration and, the more recently set up, Coxib and traditional NSAID Trialists' (CNT) Collaboration has continued its work on several fronts leading to a high profile publication in the Lancet in 2013 on the vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. A novel element of these analyses was that treatment effects were estimated by comparing the results of trials of a coxib versus placebo and trials of a coxib versus traditional NSAID. The conditions under which such indirect comparisons might be expected to yield valid results were satisfied, since the two sets of trials involved similar doses of coxibs and similar populations, and different studies used the same (high-dose) tNSAID regimens as comparators. This enabled the quantification of the hazards of various NSAIDs which had been substantially uncertain in the past. This work was widely reported in the scientific and lay media.
 
Guideline Title NICE Guideline (CG181): Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
Description NICE Guideline: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
Impact Stains should be considered for a much wider group of patients, including those with diabetes and chronic kidney disease and if there estimated 10-year risk of cardiovascular disease is 10% or more.
URL http://www.nice.org.uk/guidance/cg181
 
Description BHF Centre for Research Excellence
Amount £43,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description MRC Training Fellowship
Amount £234,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2008 
End 05/2012
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Brigham and Women's Hospital
Department Division of Cardiovascular Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Catholic University of the Sacred Heart
Department School of Medicine (UCSC)
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Florida Atlantic University
Department Charles E. Schmidt College of Science
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Italian Auxological Institute
Country Italy 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Department Clinical Gerontology
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Monash University
Department Department of Epidemiology and Preventive Medicine
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955)
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Brigham and Women's Hospital
Department Department of Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Harvard University
Department Department of Epidemiology
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Haukeland University Hospital
Department Department of Heart Disease
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation McMaster University
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Paris 13 University
Department Research Unit on Nutritional Epidemiology, INSERM U557
Country France 
Sector Multiple 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Radboud University Nijmegen Medical Center
Department Department of Endocrinology
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Royal Perth Hospital
Department Department of Neurology
Country Australia 
Sector Hospitals 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Stanford University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation United States Department of Veterans Affairs
Country United States 
Sector Public 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation University Hospital of North Norway
Department Department of Heart Disease
Country Norway 
Sector Hospitals 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation University of Bergen
Department Institute of Medicine
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation University of North Carolina at Chapel Hill
Department UNC School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation University of Nottingham
Department Division of Epidemiology and Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation VA Boston Healthcare System
Department Massachusetts Veterans Epidemiology Research and Information Center
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cancer Collaboration 
Organisation Western University
Department Department of Clinical Neurological Sciences
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual patient data from their randomised trials.
Impact This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9).
Start Year 2006
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation Brigham and Women's Hospital
Department Department of Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Department Department of Nutrition and Public Health Intervention Research
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation Maastricht University (UM)
Department School for Public Health and Primary Care Maastricht
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation McMaster University
Department Population Health Research Institute
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Sorbonne-Paris-Cité, UMR Inserm, Paris, France
Country France 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Bergen
Department Department of Global Public Health and Primary Care (IGS)
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Glasgow
Department Institute of Cardiovascular and Medical Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Gothenburg
Department Sahlgrenska Academy
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Otago
Department Department of Human Nutrition
Country New Zealand 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Wageningen
Department Division of Human Nutrition
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description B-Vitamins Cognitive Function Collaboration 
Organisation University of Western Australia
Department School of Medicine and Pharmacology
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease.
Collaborator Contribution Collaborators provide individual level patient data from their randomised trials.
Impact None.
Start Year 2008
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation ANMCO Research Centre
Country Italy 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Auckland City Hospital
Country New Zealand 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Bayer
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Bristol-Myers Squibb
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Churchill Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Erasmus University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Fred Hutchinson Cancer Research Center (FHCRC)
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Glasgow Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Hamilton Health Sciences
Country Canada 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Hennepin County Medical Center
Department Division of Clinical Epidemiology
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Jacksonville Centre for Clinical Research
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation John Radcliffe Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation King's College London
Department Cardiovascular Division
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Multiple 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Department Consorzio Mario Negri Sud (CMNS)
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Department Consorzio Mario Negri Sud (CMNS)
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation McMaster University
Department Population Health Research Institute
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mitsukoshi Health & Welfare Foundation
Country Japan 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation National Heart, Lung, and Blood Institute (NHLBI)
Country United States 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Nordic School of Public Health
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Oslo University Hospital
Department Department of Cardiology
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Oslo University Hospital
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Pfizer Global R & D
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Pharma Clinical
Country Israel 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Rikshospitalet , Sogsnsavvsveien
Country Norway 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Rosalin Franklin University
Department School of Medicine Rosalin Franklin
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Royal London Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Russells Hall Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sahlgrenska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sahlgrenska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sheba Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sheba Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation St Mary's Hospital, London
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation State University of New York
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Tokai University
Country Japan 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Ulleval University Hospital
Country Norway 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation United States Department of Veterans Affairs
Country United States 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College London Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University Hospital, Josef-Schneider-Str 2, Germany
Department Division of Nephrology
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University Hospitals of Cleveland
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Dundee
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Glasgow
Department School of Medicine Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Gothenburg
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Iowa
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of North Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Sydney
Department Sydney Medical School
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas
Department School of Public Health Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas Health Science Center San Antonio, BrainMap Database
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas Southwestern Medical Center
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Wurzburg
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Uppsala University
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation VU University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Wake Forest University
Department Wake Forest School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation American University of Beirut
Department Epidemiology and Population Health Department
Country Lebanon 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Beijing Huilongguan Hospital
Country China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Cleveland Clinic
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Ecological Institute of Caspian Sea
Country Iran, Islamic Republic of 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Firat University
Country Turkey 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Gastrointestinal & Other Cancers Research Group
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Georgetown University
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Hospital of Psychiatry and Psychotherapy, Germany
Country Germany 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Icahn School of Medicine at Mount Sinai
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Johns Hopkins Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Johns Hopkins University
Department Johns Hopkins Bloomberg School of Public Health
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation King Fahd Hospital, Saudi Arabia
Country Saudi Arabia 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Linkoping University
Department University Medical School Linkoping
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation MAM College of Pharmacology
Country India 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Massachusetts General Hospital
Department Cancer Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Mexican Social Security Insitute (IMSS)
Country Mexico 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation New York University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Northwestern University
Department Feinberg School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Ogun State University Teaching Hospital (OSUTH)
Country Nigeria 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Queen's Medical Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Rush University Medical Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Sasaki Institute
Country Japan 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Schulthess Clinic
Country Switzerland 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Seoul National University
Country Korea, Republic of 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Statistics Collaborative
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Taipei Veterans General Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Thrombosis Center of Buenos Aires
Country Argentina 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tisch Hospital
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Toronto General Hospital
Country Canada 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tri-Services General Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tripler Medical Army Center, US
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tufts University
Department School of Dental Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Arizona
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Cagliari
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Chieti-Pescara
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Louisville
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Lyon
Country France 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Maryland
Department School of Medicine Maryland
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Ottawa
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Pennsylvania
Department Institute for Translational Medicine and Therapeutics (ITMAT)
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Utah
Department School of Medicine Utah
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Zagreb
Country Croatia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Zaragoza
Country Spain 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Vanderbilt University
Department Vanderbilt Medical Center
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Member of Commission on Human Medicine Expert Working Group 
Organisation Commission on Human Medicines (CHM)
Country United Kingdom 
Sector Public 
PI Contribution Member of the Expert Working Group
Collaborator Contribution organising body
Impact n/a
Start Year 2014
 
Description New collaboration for MTT Collaboration 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution New collaboration for Marfan Treatment Trialists' Collaboration
Collaborator Contribution New collaboration for Marfan Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation Catholic University Medical School
Country Italy 
Sector Academic/University 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation McMaster University
Country Canada 
Sector Academic/University 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation University Hospitals Birmingham NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation University of Maryland
Department Department of Physical Therapy and Rehabilitation Science
Country United States 
Sector Hospitals 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description New collaborations for Gastroprotectant Treatment Trialists' Collaboration 
Organisation Yale University
Country United States 
Sector Academic/University 
PI Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Collaborator Contribution New collaborations on the Gastroprotectant Treatment Trialists' Collaboration
Impact N/A
Start Year 2016
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Cedars-Sinai Medical Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Florey Neurosciences Institute Melbourne Australia
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation George Institute for Global Health
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Helsinki University Central Hospital
Country Finland 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Mayo Clinic
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation National Cerebral and Cardiovascular Centre
Country Japan 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Stanford University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Alabama at Birmingham
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Edinburgh
Department School of Molecular and Clinical Medicine Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Glasgow
Department School of Medicine Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Melbourne
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Academic Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Antwerp University Hospital
Department Center for Medical Genetics
Country Belgium 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation BC Children's Hospital
Department Children's Heart Centre
Country Canada 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Bichat-Claude Bernard Hospital
Department French National Reference Centre for Marfan Syndrome
Country France 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Boston Children's Hospital
Country United States 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Fondazione IRCCS Policlinico San Matteo
Country Italy 
Sector Charity/Non Profit 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation National Heart, Lung, and Blood Institute (NHLBI)
Country United States 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation National Taiwan University
Department Department of Pediatrics
Country Taiwan, Province of China 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation New England Research Institutes Watertown
Country United States 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Royal Brompton Hospital
Department Clinical Trials and Evaluation Unit
Country United Kingdom 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University College London
Department Institute of Cardiovascular Science
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University of East Anglia
Department Faculty of Medicine and Health Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University of Ghent
Department Centre for Medical Genetics
Country Belgium 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Vall d'Hebron University Hospital
Department Department of Cardiology
Country Spain 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description American Heart Association Science Symposium 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The American Heart Association annual scientific meeting
Year(s) Of Engagement Activity 2016
URL http://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ScientificSessions/UCM_...
 
Description Aspirin risks outweigh vascular benefits in healthy: Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release resulted in following media coverage:

An aspirin a day can do more harm than good: Daily Mail, p.39, 29/05/2009 http://www.dailymail.co.uk/health/article-1189355/An-aspirin-day-harm-good.html
Aspirin can put patients at risk: Daily Express, p.9, 29/05/2009
http://www.express.co.uk/posts/view/104077/Aspirin-can-put-patients-at-risk
Routine aspirin benefits queried: BBC News Online, 29/05/2009
Do the potential side-effects make aspirin a bitter pill to swallow?: The Times, p.11, 01/06/2009


To highlight to patients and doctors the risks of aspirin in healthy people.
Year(s) Of Engagement Activity 2009
 
Description Benefits and safety of statins in lower-risk people: Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release resulted in following media coverage:

Statins for all over-50s to reduce heart deaths: The Daily Telegraph, front page, 17/05/12 http://www.telegraph.co.uk/health/healthnews/9269027/All-over-50s-should-be-taking-statins.html
Why everyone over 50 needs to be taking statins: Daily Mail, p. 3, 17/05/12
http://www.dailymail.co.uk/health/article-2145558/Why-EVERYONE-50-needs-taking-statins-Cholesterol-busting-pills-cut-risk-heart-attack-stroke.html?ito=feeds-newsxml
Statin drugs 'can benefit all the over-50s': The Times online, 17/05/12
http://www.thetimes.co.uk/tto/science/medicine/article3417234.ece
'Give statins to everyone over 50': Daily Express, p. 7, 17/05/12
http://www.express.co.uk/posts/view/320619/Give-statins-to-everyone-over-50
Up to 20m people should be prescribed statins, study says: The Guardian, p. 6, 17/05/12
http://www.guardian.co.uk/society/2012/may/17/statins-benefit-millions-heart-health?newsfeed=true
Statins 'could benefit the healthy': The Independent, 17/05/12
http://www.independent.co.uk/life-style/health-and-families/health-news/statins-could-benefit-the-healthy-7762347.html
Blanket protection: The Sunday Times, 'Briefing', p. 20, 20/05/12
http://www.thesundaytimes.co.uk/sto/comment/regulars/briefing/article1041917.eceStatin therapy may even benefit healthy - study: Channel 4 news online, 17/05/12
http://www.channel4.com/news/statin-therapy-may-even-benefit-healthy-study
Statins advised for over 50s: Sky News online, 17/05/12
http://news.sky.com/home/article/16229656
Guideline for statin therapy 'should be reconsidered': ITV News online, 17/05/12
http://www.itv.com/news/update/2012-05-17/guideline-for-statin-therapy-should-be-reconsidered/
Should people with a low risk of heart disease take statins? The Week, 17/05/2012
http://www.theweek.co.uk/health-science/46978/should-people-low-risk-heart-disease-take-statins#ixzz1vCtkclpv
Help for hearts: Oxford Mail, In Brief, p.5, 18/05/2012
Statins 'may even help healthy over-50s': NHS Choices website, 17/05/2012
http://www.nhs.uk/news/2012/05may/Pages/statins-may-help-for-healthy-middle-aged-adults.aspx
'Everyone above 50 must take statins regularly': Times of India online, via PTI, 18/05/2012
http://timesofindia.indiatimes.com/home/science/Everyone-above-50-must-take-statins-regularly/articleshow/13240272.cms
'Everyone above 50 should take statins regularly': Financial Express (India), 17/05/2012
http://www.financialexpress.com/news/everyone-over-50-years-should-take-statins-regularly/950659/
All over 50s should be taking statins to avoid heart attack: Newstrack India (via ANI), Unattributed, 17/05/12
http://www.newstrackindia.com/newsdetails/2012/05/17/96-All-over-50s-should-be-taking-statins-to-avoid-heart-attack.html
Statins could benefit health of millions: Gulf Times (Qatar), 17/05/2012
Statins 'could benefit the healthy': Kuwait News Agency, Unattributed, 17/05/12
http://www.kuna.net.kw/ArticleDetails.aspx?id=2241098?uage=en
BBC News online: NHS 'should consider giving statins to healthy people': 17/05/12
http://www.bbc.co.uk/news/health-18091708
Statins 'could save a lot of lives':
Daily Telegraph online (with ITN productions), 17/05/12. Online video report: Jeremy Pearson from the British Heart Foundation discusses the Oxford findings and their implications.
http://www.telegraph.co.uk/health/healthnews/9272279/Statins-could-save-a-lot-of-lives.html
Radio: BBC Radio 4 Today Programme: 17/05/12, 07:53
http://news.bbc.co.uk/today/hi/today/newsid_9721000/9721511.stm
Radio: BBC World Service Newshour: 17/05/2012, 14:19; BBC Radio 2: 17/05/12, 05:18; BBC London: 17/05/2012, 08:19, 10.02; BBC Radio Oxford: 17/05/2012, 14:01; BBC Radio West Midlands: 17/05/2012, 13:14; BBC Radio Sheffield: 17/05/2012, 07:03; BBC Radio Somerset: 17/05/12, 05:51; LBC 97.3: 17/05/12, 03:23, 07.23, 08:57;
TV: Sky News Press Preview: 16/05/12, 21:51, 22:43; Sky News: 18/05/12, 00:39


To highlight to patients and doctors the benefits and risks of statins in lower-risk people.
Year(s) Of Engagement Activity 2012
 
Description Engagement with Green Templeton College medical students 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Presentation about meta-analyses conducted at CTSU
Year(s) Of Engagement Activity 2016
 
Description European Society of Cardiology 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The European Society of Cardiology Congress for 2016, held in Rome
Year(s) Of Engagement Activity 2016
URL https://www.eurolink-tours.com/2016/esc/
 
Description Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group (re. process of writing a new curriculum for pharmaceutical medicine specialty training). This curriculum will include a set of specialty-specific Capabilities in Practice, together with the GMC's Generic Professional Capabilities.
Year(s) Of Engagement Activity 2018
 
Description Freeland School visit 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact • Interactive game aimed at children to explain what data is and its different types hosted by the VOG Research Team (note : this is being developed further by them going to Freeland Primary School in March 2019 for a full day to deliver this game to all year groups).
Year(s) Of Engagement Activity 2019
 
Description Lecture to Abingdon ATOM science festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Gave a lecture about my owrk: Treatment of vascular disease; preventing heart disease and strokes
Year(s) Of Engagement Activity 2015
 
Description Media coverage 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Media exposure as a result of the scientific paper published that examined the benefits of statins to women. Coverage was international and included Reuters, Science Daily, Medscape and national newspapers.
Year(s) Of Engagement Activity 2015
 
Description Merits of considering more extensive use of statins: Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release resulted in following media coverage:

Give statins to all over-50s: Daily Mail, p. 1, 29/08/12 http://www.dailymail.co.uk/health/article-2194892/All-50s-statins-regardless-health-history-says-Oxford-professor.html
Statins fear is 'putting patient's health at risk', researchers say: Daily Telegraph, p. 1, 29/08/12
http://www.telegraph.co.uk/health/healthnews/9504753/Statins-fear-is-putting-patients-health-at-risk-researchers-say.html
Heart drugs for all over-50s call: Daily Mirror, p. 16, 29/08/12
Give cholesterol-busting statins to all over-50s: Daily Express, p. 11, 29/08/12
http://www.express.co.uk/posts/view/342728/-Cholesterol-busting-statins-should-be-given-to-ALL-over-50s-
Statin 'for everyone over 50': The Sun, p. 20, 29/08/12
Oxford professor re-ignites statins row: The Times online, 29/08/12
http://www.thetimes.co.uk/tto/health/news/article3521615.ece
Health expert says statins should be taken by everyone over 50, even the healthy:
The Herald Sun online (Australia), 29/08/12
http://www.heraldsun.com.au/news/national/health-expert-says-statins-should-be-taken-by-everyone-over-50-even-the-healthy/story-fndo471r-1226461088762
TV: ITV 1 Daybreak: 29/08/12, 06:05; BBC News: 28/08/12, 23:27; ITV 1 South Meridian Tonight: 29/08/12, 6.08pm; BBC News Channel: 29/08/12, 11.27pm
Radio: BBC Radio Wales Good Morning Wales: 29/08/12, 06:18; BBC Radio Northampton: 29/08/12, 06:13; BBC Radio Foyle: 29/08/12, 1.56pm; BBC Radio Leeds: 29/08/12, 10.36am


To highlight to doctors and the public the merits of more extensive use of statins.
Year(s) Of Engagement Activity 2012
 
Description Merits of more intensive use of statins: Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release resulted in the following media coverage:

More potent statins 'could save thousands every year': The Daily Telegraph, p. 1, 09/11/10 http://www.telegraph.co.uk/health/8117635/More-potent-statins-could-save-thousands.html
New wonder statin 'could save thousands' at risk of heart attacks or strokes: Daily Mail, 09/11/2010
http://www.dailymail.co.uk/health/article-1327943/New-wonder-statin-save-thousands-risk-heart-attacks-strokes.html?ito=feeds-newsxml
Statin is new wonder drug: Daily Express, p. 1, 09/11/10
http://www.dailyexpress.co.uk/posts/view/210424
Aggressive use of statins further cuts cardio risk: study: Independent, 10/11/10
http://www.independent.co.uk/life-style/health-and-families/aggressive-use-of-statins-further-cuts-cardio-risk-study-2129947.html
Stronger statins 'could save lives': Daily Mirror, 09/11/10
http://www.mirror.co.uk/news/latest/2010/11/09/stronger-statins-could-save-lives-115875-22703591/
Statin increase 'will save lives': BBC News Online, 09/11/2010
http://www.bbc.co.uk/news/health-11712569
Higher Dose Statins Could Save Lives: Sky News Online, 09/11/2010
http://news.sky.com/skynews/Home/UK-News/Higher-Dose-Statins-Could-Save-Lives-According-To-Report-By-UK-And-Australian-Scientists/Article/201011215797761?lpos=UK_News_First_Home_Page_Feature_Teaser_Region_0&lid=ARTICLE_15797761_Higher_Dose_Statins_Could_Save_Lives_According_To_Report_By_UK_And_Australian_Scientists
Aggressive statins use cuts heart risk: Sydney Morning Herald, 09/11/10
http://news.smh.com.au/breaking-news-world/aggressive-statins-use-cuts-heart-risk-20101109-17l1q.html
Higher Statin Doses Linked to Fewer Heart Attacks, Stroke: US News & World Report, HealthDay blog, 09/11/10
http://health.usnews.com/health-news/diet-fitness/heart/articles/2010/11/09/higher-statin-doses-linked-to-fewer-heart-attacks-stroke.html
Aggressive use of statins further cuts cardio risk: Star (Malaysia), p. 38, 10/11/10
Radio: BBC Radio 5 Up all night, 09/11/10, 01:51am; BBC Radio Oxford, 09/11/10, 11.48am
http://www.bbc.co.uk/iplayer/episode/p00by2cc/Louisa_Hannan_09_11_2010/


To highlight amongst doctors and patients the benefits of more intensive cholesterol lowering with statins.
Year(s) Of Engagement Activity 2012
 
Description NDPH participant panel 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation of Cholesterol Treatment Trialists' Collaboration (CTT) and Marfan Treatment Trialists' Collaboration (MTT) to the Nuffield Department of Population Health Participant Panel
Year(s) Of Engagement Activity 2017
URL https://www.ctsu.ox.ac.uk/research/participant-panel
 
Description No benefit from lowering homocysteine: Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release resulted in following media coverage:

Regimens: Lower Homocysteine and Heart Risk: New York Times online, 28/06/10 http://www.nytimes.com/2010/06/29/health/research/29regi.html?scp=1&sq=jane%20armitage&st=cse
More Evidence That B Vitamins Alone Won't Counter Heart Risks: BusinessWeek, 22/06/2010?
Study: Folic Acid, B12 Don't Lower Heart Disease Risks: TIME, 22/06/2010?
http://www.time.com/time/health/article/0,8599,1998885,00.html?xid=rss-topstories
Study: Folic Acid Doesn't Cut Heart-Attack Risk: Newsweek, 22/06/2010?
http://www.newsweek.com/2010/06/22/observe-and-report.html
SEARCH published: No CV benefit on reducing homocysteine: TheHeart.Org, 22/06/2010?
Is new gene analysis the final chapter in the homocysteine saga? TheHeart.org, 21/02/2012
More Doubt on Link Between a Blood Chemical and Heart Disease: MSN Health (USA, via HealthDay newswire), 21/02/2012
More Doubt on Link Between a Blood Chemical and Heart Disease: DoctorsLounge (USA, via HealthDay newswire), 21/02/2012
http://www.doctorslounge.com/index.php/news/hd/26930


To clearly demonstrate to doctors and patients that homocysteine was not effective in reducing heart disease risk.
Year(s) Of Engagement Activity 2010
 
Description Oxford Open Doors 2018 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Open day for the general public, with talks and interactive activities.
Year(s) Of Engagement Activity 2018
 
Description Press release: Common painkillers increase heart attack risk 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Media coverage:

http://www.wired-gov.net/wg/wg-news-1.nsf/0/2993B5F1662159E780257B7C0043B5D0?OpenDocument
http://www.pharmatimes.com/Article/13-05-31/Long_term_painkiller_use_linked_to_heart_risk.aspx
http://www.bbc.co.uk/mundo/noticias/2013/05/130530_salud_analgesico_riesgo_gtg.shtml
http://www.midsussextimes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.harboroughmail.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.bournelocal.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.louthleader.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.fenlandcitizen.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.cotswoldjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.bucksherald.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.wscountytimes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.tringtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.leightonbuzzardonline.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.westsussextoday.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606
http://www.biggleswadetoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.thametoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.granthamjournal.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.rugbyadvertiser.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.bostonstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.haylingtoday.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606
http://www.lutterworthmail.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.thisischeshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.witneygazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.meltontimes.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.herefordtimes.com/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.hemeltoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.hastingsobserver.co.uk/news/regional-news/study-in-painkiller-dosage-warning-1-5143606
http://www.lynnnews.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.confused.com/health-insurance/news/study-in-painkiller-dosage-warning-2571
http://www.bognor.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606
http://www.dissexpress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.lutontoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.yorkpress.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.kenilworthweeklynews.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.banburyguardian.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.portsmouth.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.suffolkfreepress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.dunstabletoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.wandsworthguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.burytimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.eastbourneherald.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.dudleynews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.miltonkeynes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.leamingtoncourier.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.buryfreepress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.sleafordstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.buckinghamtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.marketrasenmail.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.crawleyobserver.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606
http://www.rutland-times.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.cravenherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.skegnessstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.droitwichadvertiser.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.bedfordtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.newmarketjournal.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.congletonguardian.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.daventryexpress.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.hillingdontimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.peterboroughtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.borehamwoodtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.petersfieldpost.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.horncastlenews.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.warwickcourier.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.ealingtimes.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.thelancasterandmorecambecitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.hertfordshiremercury.co.uk/Hertfordshire/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf
http://www.haverhillecho.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.spaldingtoday.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.ellesmereportpioneer.co.uk/ellesmere-port-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-55940-33403855/
http://icburton.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403719%26siteid=82449-name_page.html
http://www.formbytimes.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-66401-33403807/
http://www.bedfordshire-news.co.uk/News/UK-and-world-news/Study-in-painkiller-dosage-warning-1-7455347.xnf
http://www.falmouthpacket.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.harlowstar.co.uk/News/National-News/Study-in-painkiller-dosage-warning-1-7455347.xnf
http://icwalsall.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403839%26siteid=60240-name_page.html
http://www.theadvertisergroup.co.uk/Daily-News/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf
http://www.solihullnews.net/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning-105074-33403583/
http://www.littlehamptongazette.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.northamptonchron.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.crewechronicle.co.uk/crewe-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-96135-33403631/
http://www.chichester.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422
http://www.southportvisiter.co.uk/southport-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-101022-33403599/
http://www.runcornandwidnesweeklynews.co.uk/runcorn-widnes-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-55368-33403863/
http://www.hertsandessexobserver.co.uk/News/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf
http://www.wirralnews.co.uk/wirral-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-80491-33403759/
http://www.harrowobserver.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-116451-33403503/
http://icsuttoncoldfield.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403887%26siteid=52630-name_page.html
http://www.osadvertiser.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-80904-33403743/
http://www.uxbridgegazette.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-113046-33403527/
http://icwolverhampton.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403639%26siteid=94950-name_page.html
http://www.crosbyherald.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-68459-33403791/
http://www.examiner.co.uk/news/national-news/2013/05/30/study-in-painkiller-dosage-warning-86081-33403703/
http://www.fulhamchronicle.co.uk/fulham-and-hammersmith-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-82029-33403735/
http://www.chesterchronicle.co.uk/chester-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-59067-33403847/
http://www.enfieldindependent.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.ealinggazette.co.uk/ealing-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-64767-33403815/
http://www.blackburncitizen.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.mkweb.co.uk/News/UK-and-World-News/Study-in-painkiller-dosage-warning-2-7455347.xnf
http://www.liverpooldailypost.co.uk/liverpool-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-99623-33403607/
http://iccheshireonline.icnetwork.co.uk/0100news/0300nationalnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403927%26siteid=50020-name_page.html
http://www.buckinghamshireadvertiser.co.uk/south-buckinghamshire-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-82398-33403727/
http://www.loughboroughecho.net/news/national-news/2013/05/30/study-in-painkiller-dosage-warning-73871-33403783/
http://www.talktalk.co.uk/news/uk/article/study-in-painkiller-dosage-warning/89834/
http://www.standard.co.uk/panewsfeeds/study-in-painkiller-dosage-warning-8636891.html
http://www.buckinghamshireexaminer.co.uk/south-bucks-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-114018-33403511/
http://www.chelmsfordweeklynews.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.express.co.uk/news/uk/403637/Study-in-painkiller-dosage-warning
http://icsolihull.icnetwork.co.uk/news/national/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403663%26siteid=91411-name_page.html
http://www.belfasttelegraph.co.uk/news/local-national/uk/study-in-painkiller-dosage-warning-29307237.html
http://www.yeovilexpress.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.romseyadvertiser.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.thurrockgazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.durhamtimes.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.thisishampshire.net/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.malverngazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.brentwoodweeklynews.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.kidderminstershuttle.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.creweguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.watfordobserver.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.southwalesargus.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thewestmorlandgazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thisisoxfordshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.barryanddistrictnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.banburycake.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.chorleycitizen.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.gazetteandherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.southendstandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.stalbansreview.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.newsshopper.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.wirralglobe.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.winsfordguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.middlewichguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thisislocallondon.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thenorthernecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.ludlowadvertiser.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.boatingcornwall.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.prestoncitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/?ref=nt
http://www.eveshamjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.businessdorset.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.northwichguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.sthelensstar.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.dailyecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.westerntelegraph.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.southwestfarmer.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.kingstonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.heraldseries.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/?ref=nt
http://www.thisislancashire.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.wiltsglosstandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.walesfarmer.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.maldonandburnhamstandard.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.theboltonnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.wiltshirebusinessonline.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.bridportnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.bournemouthecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.somersetcountygazette.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.lancashiretelegraph.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thisisthewestcountry.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.gazetteherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.croydonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.stourbridgenews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.theargus.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.oxfordmail.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.harrowtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.basingstokegazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.bridgwatermercury.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.burnleycitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.warringtonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.leighjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.oxfordtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.messengernewspapers.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.salisburyjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.knutsfordguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.campaignseries.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.prestwichandwhitefieldguide.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.times-series.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.haringeyindependent.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.ledburyreporter.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.echo-news.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.harwichandmanningtreestandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.thisiswiltshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.guardian-series.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.stroudnewsandjournal.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/
http://www.hampshirechronicle.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.basildonrecorder.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://news.uk.msn.com/uk/study-in-painkiller-dosage-warning
http://ictamworth.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403687%26siteid=86764-name_page.html
http://iclichfield.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403543%26siteid=108911-name_page.html
http://www.shropshirestar.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/
http://www.expressandstar.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/
http://www.hounslowchronicle.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-109642-33403535/
http://www.hinckleytimes.net/news-in-hinckley/uk-news/2013/05/30/study-in-painkiller-dosage-warning-105367-33403575/
http://www.thisisguernsey.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/
http://www.thisisjersey.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/
http://www.stamfordmercury.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422
http://www.sussexexpress.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606
http://www.pulsetoday.co.uk/clinical/therapy-areas/pain-relief/consider-switch-to-naproxen-in-arthritis-patients-gps-urged/20003119.article
http://www.halesowennews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-common-painkillers-ibuprofen-and-diclofenac-to-increased-risk-of-heart-attack-8636745.html
http://www.ageuk.org.uk/latest-news/painkillers-linked-to-heart-disease/
http://www.gponline.com/News/article/1184344/common-painkillers-raise-heart-risks/
http://www.netdoctor.co.uk/interactive/news/common-painkillers-linked-to-heart-attack-risk-id801591952-t116.html
http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-overthecounter-painkillers-to-increased-risk-of-heart-attack-8636745.html
http://www.medicalnewstoday.com/articles/261183.php
http://www.bioportfolio.com/news/article/1483535/Painkillers-Slightly-Increase-Heart-Risk.html
http://www.arthritisresearchuk.org/news/general-news/2013/may/some-nsaids-linked-to-small-but-significant-increase-in-heart-attack-risk.aspx
http://www.bioportfolio.com/news/article/1483943/Some-NSAIDs-linked-to-small-but-significant-increase-in-heart-attack-risk.html
http://www.noodls.com/viewNoodl/18803229/university-of-oxford-/small-increase-in-heart-risk-from-common-painkillers
http://www.ox.ac.uk/media/news_stories/2013/130530.html
http://www.express.co.uk/news/health/403652/Most-arthritis-victims-need-not-worry-about-painkiller-risks
http://www.guardian.co.uk/science/2013/may/30/painkillers-heart-attack-risk-study
http://www.pharmaceutical-int.com/news/painkillers-found-to-increase-heart-problems.html
http://www.bbc.co.uk/news/health-22713613
http://www.bbc.co.uk/indonesia/majalah/2013/05/130529_iptek_obat_jantung.shtml
http://www.dailystar.co.uk/latestnews/view/317404/Study-in-painkiller-dosage-warning/
http://www.heraldscotland.com/news/health/painkiller-use-linked-to-bigger-risk-of-heart-attack.21212962
http://www.wiltshiretimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/
http://www.itv.com/news/update/2013-05-30/professor-risks-are-relative-to-medical-background/
http://www.huffingtonpost.co.uk/2013/05/30/health-high-doses-painkillers-heart-risk_n_3356911.html
http://www.dailymail.co.uk/health/article-2333067/Painkillers-taken-millions-increase-heart-risk-Prolonged-use-leads-significant-danger.html?ico=home%5Eheadlines
http://www.mailonsunday.co.uk/health/article-2333067/Painkillers-taken-millions-increase-heart-risk-Prolonged-use-leads-significant-danger.html
http://www.manchesterwired.co.uk/news.php/1486945-Common-painkillers-pose-heart-risk
http://www.ukwirednews.com/news.php/1486945-Common-painkillers-pose-heart-risk
http://www.bbc.co.uk/news/health-22694858
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61128-9/fulltext
http://uk.reuters.com/article/2013/05/29/us-painkillers-risks-idUKBRE94S1FV20130529
http://www.yorkshirepost.co.uk/news/at-a-glance/general-news/high-painkiller-doses-found-to-raise-risk-of-heart-attack-or-stroke-1-5721318
http://metro.co.uk/2013/05/30/painkillers-may-increase-risk-of-heart-attacks-strokes-and-death-3817327/
http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-painkillers-to-increased-risk-of-heart-attack-8636745.html
http://www.express.co.uk/news/health/403581/Heart-risks-for-high-dose-users-of-painkillers
http://www.express.co.uk/news/health/403576/Why-Ibuprofen-report-is-good-news
http://source.meltwaternews.com/tt/ft.com_all/article.php?which=20130529_780_5303
http://www.telegraph.co.uk/health/healthnews/10087871/Painkiller-taken-for-arthritis-is-heart-risk.html
http://medicalxpress.com/news/2013-05-meta-analysis-common-painkillers-heart-problems.html


Increased public awareness of the hazards of common painkillers.
Year(s) Of Engagement Activity 2013
 
Description Press release: Meta-analysis shows that alteplase given promptly after stroke reduces long-term disability 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Media coverage:

http://www.femtomedicine.com/prompt-administration-of-alteplase-treatment-reduces-disability-in-stroke-patients/
http://www.femtomedicine.com/alteplase-given-promptly-after-stroke-reduces-long-term-disability-even-in-older-people-those-with-severe-stroke/
http://www.femtomedicine.com/the-lancet-meta-analysis-shows-that-alteplase-given-promptly-after-stroke/
http://www.hospitaldr.co.uk/blogs/our-news/centralising-stroke-services-can-cut-deaths
http://medicalxpress.com/news/2014-08-meta-analysis-alteplase-promptly-long-term-disability.html
http://www.medicalnewstoday.com/releases/280587.php
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60584-5/fulltext



None.
Year(s) Of Engagement Activity 2014
 
Description Science Media Centre Expert Panel 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Press conference to share results of the effects of statins on the elderly: • In relation to CTT elderly paper (see: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext); attended by Colin Baigent and Boby Mihaylova; see: https://www.sciencemediacentre.org/expert-reaction-to-meta-analysis-looking-at-statins-and-cardiovascular-events-in-all-ages/.
Year(s) Of Engagement Activity 2019
 
Description Science Media Centre expert reaction briefing re: statins 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact SMC expert reaction briefing to the Lancet paper interpreting the evidence on risk and benefits of statins on 8 September 2016
Year(s) Of Engagement Activity 2016
URL http://www.sciencemediacentre.org/interpreting-the-evidence--on-the-risks-and-benefits-of-statins/
 
Description Science Media Centre press briefing re: statins 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact This was a media briefing to national and international press organisations on the Lancet paper 'Interpretation of the evidence for the efficacy and safety of statin therapy'. It tokk place on 28 June 2016
Year(s) Of Engagement Activity 2016
URL http://www.sciencemediacentre.org/the-perception-of-statins-and-the-impact-of-intense-debate-on-stat...